Alexion Pharmaceuticals

About:

Alexion Pharmaceuticals is a biopharmaceutical company that engages in the development and commercialization of mid-to-late-stage therapies.

Website: https://alexion.com

Twitter/X: AlexionPharma

Description:

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

Total Funding Amount:

$5.8M

Estimated Revenue Range:

$1B to $10B

Headquarters Location:

Cheshire, Connecticut, United States

Founded Date:

1992-01-01

Contact Email:

AdverseEventReporting(AT)alxn.com

Founders:

Joseph A.Madri, Leonard Bell, Stephen Squinto

Number of Employees:

1001-5000

Last Funding Date:

1999-02-12

IPO Status:

Public

Industries:

© 2025 bioDAO.ai